MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1

Molecular Cancer Research

Volumn 6, Issue 4, 2008, Pages 555-567

  Shen, Qiang ^a   Rahn, Jennifer J ^a   Zhang, Jing ^a   Gunasekera, Nirosha ^a   Sun, Xuejun ^a   Shaw, Andrew R E ^a   Hendzel, Michael J ^a   Hoffman, Pat ^b   Bernier, Ashlyn ^a   Hugh, Judith C ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CRK LIKE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MUCIN 1; PROTEIN CDC42; PROTEIN TYROSINE KINASE; RAC1 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CYTOSKELETON; EMBRYO; ENZYME ACTIVITY; FILOPODIUM; HUMAN; HUMAN CELL; LAMELLIPODIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

ACTINS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CA-15-3 ANTIGEN; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MICE; NIH 3T3 CELLS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TYPE C PHOSPHOLIPASES;

EID: 42049108198     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2033     Document Type: Article

References (46)

1. Braga VM, Pemberton LF, Duhig T, Gendler SJ. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 1992;115:427-37.
2. Pemberton LF, Rughetti A, Taylor-Papadimitriou J, Gendler SJ. The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. J Biol Chem 1996;271:2332-40.
3. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
4. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-82.
5. Kam JL, Regimbald LH, Hilgers JH, et al. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res 1998;58:5577-81.
6. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996;56:4244-9.
7. Kuby J. Leukocyte migration and inflammation. Immunology. 3rd ed. New York: WH. Freeman; 1997. p. 361-77.
8. Rahn JJ, Chow JW, Horne GJ, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005;22:475-83.
9. Glinskii OV, Huxley VH, Turk JR, et al. Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. Clin Exp Metastasis 2003;20:451-8.
10. Glinsky VV, Glinsky GV, Glinskii OV, et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 2003;63:3805-11.
11. Hayashi T, Takahashi T, Motoya S, et al. MUC1 mucin core protein binds to the domain 1 of ICAM-1. Digestion 2001;63 Suppl 1:87-92.
12. Wang H, Lillehoj EP, Kim KC. Identification of four sites of stimulated tyrosine phosphorylation in the MUC1 cytoplasmic tail. Biochem Biophys Res Commun 2003;310:341-6.
13. Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett 1994;356:130-6.
14. Li Y, Ren J, Yu W, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J Biol Chem 2001;276:35239-42.
15. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001;276:13057-64.
16. Ren J, Li Y, Kufe D. Protein kinase C δ regulates function of the DF3/MUC1 carcinoma antigen in β-catenin signaling. J Biol Chem 2002;277:17616-22.
17. Gonzalez-Guerrico AM, Cafferata EG, Radrizzani M, et al. Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis. J Biol Chem 2002;277:17239-47.
18. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 β and β-catenin. J Biol Chem 2001;276:6061-4.
19. Hilkens J, Wesseling J, Vos HL, et al. Involvement of the cell surface-bound mucin, episialin/MUC1, in progression of human carcinomas. Biochem Soc Trans 1995;23:822-6.
20. Rahn JJ, Shen Q, Mah BK, Hugh JC. MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J Biol Chem 2004;279:29386-90.
21. Feldner JC, Brandt BH. Cancer cell motility - on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002;272:93-108.
22. Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, Falasca M. The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration. Oncogene 2002;21:6520-9.
23. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004;23:7928-46.
24. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
25. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997;11:2295-322.
26. Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999;144:1235-44.
27. Rottner K, Hall A, Small JV. Interplay between Rac and Rho in the control of substrate contact dynamics. Curr Biol 1999;9:640-8.
28. Kiyokawa E, Hashimoto Y, Kobayashi S, Sugimura H, Kurata T, Matsuda M. Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev 1998;12:3331-6.
29. Posern G, Zheng J, Knudsen BS, et al. Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G. Oncogene 1998;16:1903-12.
30. Li L, Guris DL, Okura M, Imamoto A. Translocation of CrkL to focal adhesions mediates integrin-induced migration downstream of Src family kinases. Mol Cell Biol 2003;23:2883-92.
31. Salgia R, Pisick E, Sattler M, et al. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 1996;271:25198-203.
32. Singh PK, Wen Y, Swanson BJ, et al. Platelet-derived growth factor receptor β-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007;67:5201-10.
33. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995;55:4000-3.
34. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003;22:1324-32.
35. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the antiapoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004;279:20607-12.
36. Luscinskas FW, Gimbrone MA, Jr. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996;47:413-21.
37. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
38. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
39. Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC, Finn OJ. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol 1998;160:3111-20.
40. Thompson EJ, Shanmugam K, Hattrup CL, et al. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-κB pathways. Mol Cancer Res 2006;4:489-97.
41. Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998;392:933-6.
42. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006;107:4540-8.
43. Kaplan KB, Bibbins KB, Swedlow JR, Arnaud M, Morgan DO, Varmus HE. Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J 1994;13:4745-56.
44. Schaller MD, Parsons JT. pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Mol Cell Biol 1995;15:2635-45.
45. Nishihara H, Maeda M, Oda A, et al. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 2002;100:3968-74.
46. Oosawa Y, Imada C, Furuya K. Temperature dependency of calcium responses in mammary tumour cells. Cell Biochem Funct 1997;15:113-7.